The patent grants EntreMed composition-of-matter and method of use intellectual property protection through 2025 for analogs of 2- methoxyestradiol (2ME2) in oncology and a broad range of non-oncology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division.
Analogs of 2ME2 have been developed by EntreMed to improve metabolic stability and retain or enhance antiproliferative and antiangiogenic properties.
James Burns, president and CEO of EntreMed, said: “This patent further strengthens our intellectual property position in next generation antimitotic and antiangiogenic drugs for the treatment of cancer.”